Lycera announces research showing new, oral immunotherapy possesses potent single agent anti-cancer activity
Results were presented in a poster presentation entitled "Novel synthetic RORgamma agonist compounds as a potential anti-tumor therapeutic approach" and will be highlighted in an oral presentation on